IL6 and metabolic dysfunction-associated steatotic liver disease: Recent research has shown that PNPLA3-mediated susceptibility to NAFLD was reduced by decreasing IL-6/STAT3 activity but increasing it in wild-type liver cells, promoting NAFLD onset.